Drug Trial Radar · NCT05369052
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
865
Planned (sponsor's estimate)
Start
May 3, 2022
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- MicuRxIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Conditions
- Diabetic Foot Infection
Interventions
contezolid acefosamil (IV)/contezolid (PO)Drug
Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
Linezolid (IV and PO)Drug
Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by InvestigatorsTime frame: Day 35
- Adverse events - symptoms reported by subjectsTime frame: 28-35 days after End-of-Therapy (EOT)
- Clinical laboratory assessment - complete blood countTime frame: 28-35 days after End-of-Therapy (EOT)
- Vital signs - heart rateTime frame: 28-35 days after End-of-Therapy (EOT)
Locations
14 sites in 8 countries. Site status is shown where the registry gives one.
New Hope Research Development
Corona, California · Recruiting
ILD Research Center
Vista, California · Recruiting
MHAT Sveti Nikolay Chudotvorets EOOD
Lom, Bulgaria · Recruiting
Multiprofile Hospital for Active Treatment - KANEV
Rousse, Bulgaria · Recruiting
Medical Institute Ministry of Interior Central Clinical Base
Sofia, Bulgaria · Recruiting
University Multidisciplinary Hospital for Active Treatment and Emergency Medicine 'N. I. Priogov´
Sofia, Bulgaria · Recruiting
South-Estonian Hospital Ltd.
Võru, Estonia · Recruiting
LTD High Technology Hospital Med Center
Batumi, Georgia · Recruiting
JSC Vian - West Georgia Medical Center
Kutaisi, Georgia · Recruiting
GMV Care& Research - Maria Cecilia Hospital
Cotignola, Italy · Recruiting
Daugavpils Regional Hospital
Daugavpils, Latvia · Recruiting
Instytut Medycyny Wsi im. W. Chodzki
Lublin, Poland · Recruiting
PODEMA Sp. z o.o.
Warsaw, Poland · Recruiting
University Clinical Center Kragujevac
Kragujevac, Serbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.